GlaxoSmithKline taking pandemic vaccine orders

May 15, 2009

(AP) -- Pharmaceutical giant GlaxoSmithKline said Friday it has received orders from several countries to stockpile pandemic vaccine as soon as it gets the vaccine's key ingredient from the World Health Organization.

As the continues to spread worldwide - WHO says 34 countries have reported more than 7,500 cases - health officials are deciding when to ask vaccine makers to start making a vaccine to fight the virus.

"We expect this pattern of spread to continue," said Dr. Margaret Chan, WHO's director-general on Friday, before the U.N. health agency's yearly meeting of its 193 member states. According to WHO's pandemic alert scale, the world is currently in phase 5 of a possible 6, meaning a global flu outbreak is imminent.

About a dozen developed countries, including Canada, France and the United States, have struck advance deals with vaccine producers like PLC and Sanofi Aventis to provide pandemic vaccine as soon as their factories start producing it.

WHO will also ask vaccine producers to save a portion of their pandemic vaccines for poor nations.

A pandemic vaccine based on the swine flu virus could be available in four to six months, once companies receive the "seed stock" from WHO. That is currently being developed by the U.S. , and is expected to be ready in the next few weeks.

In a press statement, Glaxo said it had received "interest" from several governments keen to stock swine flu vaccine, including Britain, France, Belgium and Finland.

On Thursday, WHO convened a group of vaccine manufacturers and other experts to discuss issues such as when swine flu vaccine production should begin, how many doses will be needed and who should get the vaccines.

WHO flu chief Keiji Fukuda said there were no big decisions about swine flu vaccine and that more meetings would be needed before the agency made any recommendations to manufacturers.

Next week, WHO's Chan and U.N. Secretary-General Ban Ki-moon will meet with vaccine makers to discuss swine flu issues.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Study examines FDA influence on design of pivotal drug studies

add to favorites email to friend print save as pdf

Related Stories

WHO meets on production of swine flu vaccine

May 14, 2009

(AP) -- As swine flu cases hit 6,500 worldwide, World Health Organization officials were meeting with vaccine manufacturers and other experts in Geneva on Thursday to discuss making a vaccine to fight the virus.

US wants ingredient in swine flu vaccine by May

Apr 28, 2009

(AP) -- U.S. scientists hope to have a key ingredient for a swine flu vaccine ready in early May, but tell The Associated Press that the novel virus grows slowly in eggs - the chief way flu vaccines are made.

Possible seasonal shot seen for bird flu

May 04, 2006

A seasonal flu shot against a possible bird flu pandemic is reported to be under consideration by U.S. public health officials at a Singapore conference.

Unusual flu vaccine is developed

Jun 14, 2006

U.S. scientists have used reverse genetics to develop an influenza virus with two key proteins on its surface derived from the H5N1 avian virus strain.

Recommended for you

Powdered measles vaccine found safe in early clinical trials

17 hours ago

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

Health care M&A leads global deal surge

Nov 23, 2014

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.